Sitali released its 2026 interim report. The company's total operating revenue was 1.414 billion yuan, and net profit attributable to the parent company was 39.929 million yuan, ranking 98th among peer companies that have already disclosed results. Net cash inflow from operating activities was 111 million yuan, a decrease of 16.1285 million yuan, or 12.74%, compared with the same period last year. The company's latest asset-liability ratio was 58.59%, up 3.04 percentage points from the same period last year. Gross margin was 20.13%, down 2.12 percentage points from the previous quarter. ROE was 1.61%, and diluted earnings per share was 0.09 yuan. The number of shareholders was 52,200, and the top ten shareholders held 25.68% of the total share capital.
Zhejiang Starry Pharm Co LtdNet profit of 39.929 million yuan, ranking 98th among peers, with declining cash flow and margins.